Source comparison
Tesamorelin Contraindications: Safety Profile Comparison
Active malignancy IGF-1 promotes tumour cell proliferation, angiogenesis, and anti-apoptotic signalling via PI3K/AKT and MAPK pathways Accelerated tumour growth, increased metastatic potential, reduced apoptotic response to chemotherapy GLP-1 agonists (semaglu
This comparison does not assign a generated winner or score.
- Active malignancy
- IGF-1 promotes tumour cell proliferation, angiogenesis, and anti-apoptotic signalling via PI3K/AKT and MAPK pathways
- Accelerated tumour growth, increased metastatic potential, reduced apoptotic response to chemotherapy
- GLP-1 agonists (semaglutide, tirzepatide) for fat reduction without GH pathway activation
- Disrupted hypothalamic-pituitary axis
- Absence of functional somatotrophs or GHRH receptors eliminates ability to generate endogenous GH surge
- No therapeutic effect; unmasking of latent adrenal insufficiency if ACTH reserves are impaired
- Exogenous GH (if clinically indicated and axis is non-recoverable); incretin-based therapies for metabolic intervention
- Pregnancy (Category X)
- Supraphysiologic GH/IGF-1 disrupts foetal growth plate ossification and organ maturation timing; animal studies show teratogenicity
- Foetal loss, skeletal malformations, intrauterine growth abnormalities
- Delay therapy until post-lactation; lifestyle intervention during pregnancy
- Diabetic retinopathy (proliferative)
- IGF-1 upregulates VEGF, driving neovascularisation in ischaemic retinal tissue
- Worsening macular oedema, vitreous haemorrhage, vision loss despite stable glycaemic control
- Optimise glucose control; anti-VEGF intravitreal therapy; delay GH secretagogues until retinopathy stabilises
- Hypersensitivity to mannitol or tesamorelin
- IgE-mediated or non-IgE immune reaction to peptide structure or excipient
- Anaphylaxis, angioedema, bronchospasm, or delayed hypersensitivity reaction
- Avoidance; no desensitisation protocol exists for GHRH analogues
- Critical illness
- Functional GH resistance (elevated GH but suppressed hepatic IGF-1 production due to inflammatory cytokines)
- No metabolic benefit; increased infection risk, worsened hyperglycaemia
- Defer until recovery; standard critical care metabolic support